LCG
CLVS

Lisanti Capital Growth’s Clovis Oncology, Inc. CLVS Stock Holding History

Lisanti Capital Growth’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,395
Closed -$216K – 127
2017
Q1 		$216K Buy
+3,395
New +$206K 0.31% 87
2016
Q4 		– Sell
-6,505
Closed -$235K – 111
2016
Q3 		$235K Buy
+6,505
New +$140K 0.3% 93
2015
Q3 		– Sell
-7,150
Closed -$628K – 100
2015
Q2 		$628K Sell
7,150
-7,630
-52% -$653K 0.45% 76
2015
Q1 		$1.1M Buy
+14,780
New +$1.04M 0.63% 82

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Lisanti Capital Growth's CLVS Position: Q2 2017 in Review

Lisanti Capital Growth sold out of Clovis Oncology, Inc. (CLVS) in Q2 2017, closing a stake of 3,395 shares — an estimated $216K sold.

Lisanti Capital Growth first reported a position in CLVS in Q1 2015 and held it in 4 quarters. The position peaked at $1.1M in Q1 2015. 271 funds tracked by Wall St. Rank hold CLVS as of Q2 2017.

  • Lisanti Capital Growth reported no remaining Clovis Oncology, Inc. position as of Q2 2017 after selling out during the quarter.
  • Lisanti Capital Growth sold 3,395 Clovis Oncology, Inc. shares in Q2 2017, an estimated $216K.
  • Lisanti Capital Growth first reported a position in Clovis Oncology, Inc. in Q1 2015 and held it in 4 quarters.
  • Lisanti Capital Growth's Clovis Oncology, Inc. position peaked at $1.1M in Q1 2015.
  • 271 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2017.

Based on Lisanti Capital Growth's 13F filing for Q2 2017, filed 28 Jul 2017.